Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes:;Interleukin- 1 receptorantagonistbehandling af patienter med type 2-diabetes - Sekundærpublikation

Ugeskrift for Laeger

Volumn 169, Issue 45, 2007, Pages 3868-3871

  Larsen, Claus Morten ^a   Faulenbach, Mirjam ^a   Vaag, Allan ^a   Vølund, Aage ^a   Ehses, Jan ^a   Seifert, Burkhardt ^a   Mandrup Poulsen, Thomas ^a   Donath, Marc ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38749146294     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Cerasi E, Luft R. Insulin response to glucose infusion in diabetic and non-diabetic monozygotic twin pairs. Acta Endocrinol. (Copenh) 1967;55:330-45.
2. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667-87.
3. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995;44:1249-58.
4. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996;39:1005-29.
5. Bendtzen K, Mandrup-Poulsen T, Nerup J et al. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986;232:1545-7.
6. Maedler K, Sergeev P, Ris F et al. Glucose-induced beta-cell production of interleukin-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002;110:851-60.
7. Maedler K, Sergeev P, Ehses JA et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci U S A 2004;101:8138-43.
8. Vaag A, Alford F, Henriksen FL et al. Multiple defects of both hepatic and peripheral intracellular glucose processing contribute to the hyperglycaemia of NIDDM. Diabetologia 1995;38:326-36.